Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.66%0700.HK-6.20%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.44%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.65%0857.HK-1.46%UNH-10.21%1288.HK-1.42%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.68%AUDUSD-1.57%AUDCAD-1.00%EURAUD+0.99%AUDCHF-0.98%GBPAUD+0.91%AUDNZD-0.87%NZDJPY-0.83%GBPJPY-0.78%EURJPY-0.73%CHFJPY-0.70%CADJPY-0.70%NZDUSD-0.70%GBPUSD-0.65%USDCHF+0.62%AUDSGD-0.62%EURUSD-0.60%USDCAD+0.59%AUDDKK-0.54%USDZAR+0.47%USDMXN+0.42%GBPTRY+0.41%USDTHB+0.39%AUDNOK-0.37%USDNOK+0.33%GBPHKD+0.32%EURZAR+0.31%NZDMXN+0.30%GBPMXN-0.28%GBPZAR+0.28%CHFNOK+0.26%NOKJPY-0.25%USDSEK+0.24%USDPLN+0.21%USDTRY+0.21%EURCNH-0.19%EURNOK+0.19%EURHKD-0.17%CHFSEK+0.16%USDILS+0.16%USDDKK+0.16%USDJPY-0.14%NZDCAD-0.13%PLNJPY-0.12%USDCNH-0.12%GBPSGD-0.11%NZDCHF-0.11%EURNZD+0.10%EURSGD-0.08%EURSEK+0.08%GBPCAD-0.08%USDSGD+0.07%EURGBP+0.06%GBPNZD+0.05%EURPLN+0.05%EURCZK+0.04%USDCOP-0.04%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%USDHKD-0.02%NZDSGD-0.02%EURCAD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.21%XAGUSD-0.81%GAGUSD-0.81%W1-0.62%HG1-0.60%XAUUSD-0.51%GAUUSD-0.51%C1-0.46%XNGUSD-0.38%S1-0.25%UKOIL+0.16%USOIL-0.10%BTCUSD-3.54%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.74%ZECUSDT-6.89%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.33%XLMUSD-3.84%BCHUSDT-3.55%LTCUSD+47.50%UNIUSD-3.16%SUIUSD-2.99%TONUSD+59.18%HBARUSDT-5.19%TAOUSDT-3.19%AAVEUSD-3.38%ONDOUSDT-5.32%ICPUSDT-2.18%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.60%ATOMUSDT-2.39%INJUSDT-7.45%STXUSDT-3.46%PYTHUSDT-0.81%TIAUSDT-3.10%FETUSDT-4.61%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-3.90%IOTAUSDT-2.52%POLUSDT-2.08%WIFUSDT-2.98%AXSUSDT-3.05%EOSUSDT-4.31%IMXUSDT-3.36%FARTCOINUSDT-6.94%GALAUSDT-2.38%DYDXUSDT-2.85%ORDIUSDT-2.64%NOTUSDT-2.34%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.66%0700.HK-6.20%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.44%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.65%0857.HK-1.46%UNH-10.21%1288.HK-1.42%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.68%AUDUSD-1.57%AUDCAD-1.00%EURAUD+0.99%AUDCHF-0.98%GBPAUD+0.91%AUDNZD-0.87%NZDJPY-0.83%GBPJPY-0.78%EURJPY-0.73%CHFJPY-0.70%CADJPY-0.70%NZDUSD-0.70%GBPUSD-0.65%USDCHF+0.62%AUDSGD-0.62%EURUSD-0.60%USDCAD+0.59%AUDDKK-0.54%USDZAR+0.47%USDMXN+0.42%GBPTRY+0.41%USDTHB+0.39%AUDNOK-0.37%USDNOK+0.33%GBPHKD+0.32%EURZAR+0.31%NZDMXN+0.30%GBPMXN-0.28%GBPZAR+0.28%CHFNOK+0.26%NOKJPY-0.25%USDSEK+0.24%USDPLN+0.21%USDTRY+0.21%EURCNH-0.19%EURNOK+0.19%EURHKD-0.17%CHFSEK+0.16%USDILS+0.16%USDDKK+0.16%USDJPY-0.14%NZDCAD-0.13%PLNJPY-0.12%USDCNH-0.12%GBPSGD-0.11%NZDCHF-0.11%EURNZD+0.10%EURSGD-0.08%EURSEK+0.08%GBPCAD-0.08%USDSGD+0.07%EURGBP+0.06%GBPNZD+0.05%EURPLN+0.05%EURCZK+0.04%USDCOP-0.04%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%USDHKD-0.02%NZDSGD-0.02%EURCAD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.21%XAGUSD-0.81%GAGUSD-0.81%W1-0.62%HG1-0.60%XAUUSD-0.51%GAUUSD-0.51%C1-0.46%XNGUSD-0.38%S1-0.25%UKOIL+0.16%USOIL-0.10%BTCUSD-3.54%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.74%ZECUSDT-6.89%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.33%XLMUSD-3.84%BCHUSDT-3.55%LTCUSD+47.50%UNIUSD-3.16%SUIUSD-2.99%TONUSD+59.18%HBARUSDT-5.19%TAOUSDT-3.19%AAVEUSD-3.38%ONDOUSDT-5.32%ICPUSDT-2.18%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.60%ATOMUSDT-2.39%INJUSDT-7.45%STXUSDT-3.46%PYTHUSDT-0.81%TIAUSDT-3.10%FETUSDT-4.61%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-3.90%IOTAUSDT-2.52%POLUSDT-2.08%WIFUSDT-2.98%AXSUSDT-3.05%EOSUSDT-4.31%IMXUSDT-3.36%FARTCOINUSDT-6.94%GALAUSDT-2.38%DYDXUSDT-2.85%ORDIUSDT-2.64%NOTUSDT-2.34%RONINUSDT-2.92%

BMS posts 56-week pediatric Camzyos data

NEWS

November 6, 2026 at 21:42 UTC

3 min read
Unbranded heart medication bottle in pediatric exam room illustrating positive Camzyos trial data for BMY

Key Points

  • 01Bristol Myers Squibb (BMY) reported 56-week Phase 3 SCOUT-HCM data for Camzyos in adolescents with symptomatic oHCM.
  • 02Among 44 enrolled patients, 43 completed the 28-week placebo-controlled phase and entered active treatment to week 56.
  • 03Continuous Camzyos treatment led to a mean 48.1 mmHg reduction in Valsalva LVOT gradient from baseline at week 56.
  • 04No new safety signals were observed, and no patient’s LVEF fell below 50% during the 56-week period.

BMS unveils 56-week SCOUT-HCM pediatric results

Bristol Myers Squibb (BMY) has reported 56-week results from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The data were presented on November 6, 2026, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago and extend the 28-week findings that supported U.S. approval for pediatric use.

SCOUT-HCM enrolled 44 pediatric patients aged 12 to under 18 years with symptomatic oHCM. Of these, 43 completed the initial 28-week randomized, double-blind, placebo-controlled period and then entered an active-treatment phase in which all patients received Camzyos through week 56.

Efficacy outcomes over 56 weeks

Patients treated with Camzyos throughout the study showed a substantial reduction in left ventricular outflow obstruction. In the continuous mavacamten arm, the mean change from baseline in Valsalva left ventricular outflow tract gradient after 56 weeks was -48.1 mmHg. Patients who initially received placebo and switched to Camzyos at week 28 experienced a similar degree of gradient reduction by week 56.

Across both treatment sequences, patients demonstrated meaningful improvements in several secondary endpoints. These included measures such as resting and postexercise LVOT gradients, exercise capacity, symptom status, and patient-reported shortness of breath, as assessed during the controlled phase of the study.

Safety profile and cardiac function

Camzyos maintained a safety profile consistent with earlier SCOUT-HCM data and adult Phase 3 studies. No new safety signals were identified over the 56-week follow-up. Treatment-related treatment-emergent adverse events were infrequent, with five events reported in the continuous mavacamten arm over 56 weeks and one in the placebo-to-mavacamten arm over 28 weeks.

Serious treatment-emergent adverse events were reported in two patients in the continuous treatment arm, with none in the crossover arm. No patient treated with Camzyos experienced a left ventricular ejection fraction below 50% during the 56-week evaluation period, and the overall safety profile in pediatric patients was comparable to that observed in adult studies.

Regulatory status and upcoming data

Camzyos is the first approved treatment for pediatric patients in the United States with symptomatic oHCM who weigh at least 30 kg. The U.S. Food and Drug Administration granted this approval in September 2026, based on positive 28-week SCOUT-HCM results in this adolescent population.

Camzyos, a selective, reversible, allosteric inhibitor of cardiac myosin, is also approved in adults with symptomatic NYHA class II–III oHCM and has been studied across multiple Phase 3 trials and long-term extensions. Bristol Myers Squibb (BMY) plans further presentations at the American Heart Association’s Scientific Sessions 2026 in Chicago, including additional clinical and real-world data and analyses from the Camzyos Risk Evaluation and Mitigation Strategy program.

Key Takeaways

  • 01The 56-week SCOUT-HCM data show sustained LVOT gradient reduction with Camzyos in adolescents with symptomatic oHCM.
  • 02Safety findings over 56 weeks align with prior pediatric and adult experience, with no new safety signals and preserved left ventricular function.
  • 03The results strengthen the evidence base that underpinned recent U.S. FDA approval of Camzyos for pediatric patients weighing at least 30 kg with symptomatic oHCM.

BMS posts 56-week pediatric Camzyos data | Trading Dashboard